LATOYA SMITH: Open Payments
NPI 1194208231 · BRIDGEPORT, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,719 in 80 payments from 20 companies in 2025. Trend: 2023 $683 · 2024 $575 · 2025 $1,719
Food & beverage: $1,719
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $392 |
| Neurocrine BioSciences, Inc. | 6 | $188 |
| Supernus Pharmaceuticals, Inc. | 9 | $180 |
| UCB, Inc. | 9 | $153 |
| Otsuka America Pharmaceutical, Inc. | 6 | $114 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $105 |
| PFIZER INC. | 3 | $72 |
| Collegium Pharmaceutical, Inc. | 3 | $67 |
| Vanda Pharmaceuticals Inc. | 2 | $62 |
| SK Life Science, Inc. | 2 | $54 |
Products named: VRAYLAR, INGREZZA, Qelbree, REXULTI, Briviact, CAPLYTA, BOTOX, NURTEC ODT.
Industry payments across CT — which companies pay providers there.
